Delving into the Latest Updates on Ornidazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Orinidazole, Ornidazole (USAN/INN), NSC-95075

+ [7]

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

AmebiasisAnaerobic bacterial infectionGiardiasis+ [1]

Inactive Indication

Dysentery, AmebicLiver Abscess, AmebicUrogenital infection by Trichomonas vaginalis

Originator Organization

Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.

Active Organization

Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 2001),

AmebiasisAnaerobic bacterial infectionGiardiasis+ [1]

Regulation-

Login to view timeline

Structure

Molecular FormulaC7H10ClN3O3

InChIKeyIPWKIXLWTCNBKN-UHFFFAOYSA-N

CAS Registry16773-42-5

Metal-organic framework (MOF) derived spherical porous carbon (SPC) has potential application value in the field of adsorption and sustained release of nitroimidazole drugs. This work used MIL-53(Fe) as a precursor and prepared spherical 3-aminophenol-formaldehyde resin containing MIL-53(Fe) crystals using the advanced Stöber method, followed by the successful preparation of MIL-53(Fe) derived SPC (MSPC) with a structure containing both micropores and mesopores through high-temperature carbonization. The effects of the doping amount of MIL-53(Fe) on the sphericity and particle size of MSPC were investigated. The drug uptake capacity and sustained release performances of MSPC for metronidazole (MNZ) and ornidazole (ONZ) were assessed through batch tests, along with an investigation into the impact of varying pH levels on the sustained release performances. The experimental findings revealed that the drug loading of MNZ and ONZ onto MSPC achieved 111 and 120 mg/g, respectively, with a sustained release time of up to 24 h. The drug loading process adhered to the Langmuir isotherm adsorption model and conformed to the pseudo-second-order kinetics model, whereas the sustained release mechanism was consistent with the Korsmeyer-Peppas model. Furthermore, cytotoxicity and cyclic drug loading experiments indicated that MSPC exhibited good biocompatibility and stability. Therefore, this study provides new ideas for the development of SPC drug carriers.

01 Dec 2024·CELL BIOCHEMISTRY AND BIOPHYSICS

Ornidazole Inhibits the Angiogenesis and Migration Abilities of Non-small Cell Lung Cancer (NSCLC) via Downregulation of VEGFA/VEGFR2/NRP-1 and PI3K/AKT/mTOR Pathways

Article

Author: Evyapan, Gulsah ; Celik, Ibrahim Seyfettin ; Senturk, Nesrin Cetinel

BACKGROUND:

Around the world, non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths among all cancers. Despite advancements in new therapeutic approaches over the past few decades, the five-year survival rate still remains disappointing. The lack of effective anti-angiogenic and anti-migration drugs is the biggest obstacle to the treatment of metastatic lung cancer. Therefore, there is a need to develop new and effective therapeutic compounds targeting anti-angiogenic and anti-migration pathways for the treatment of lung cancer. Ornidazole is a nitroimidazole agent widely used in the treatment of parasitic infections such as trichomonas vaginalis, amebiasis and giardiasis. This study aimed to investigate the anti-proliferative, anti-angiogenic and anti-mitotic activities of the anti-parasitic drug Ornidazole in two human lung cancer cell lines (A549, H1299).

METHODS:

We determined the effects of Ornidazole, on cell viability, apoptosis, migration, angiogenesis and metastatic ability against NSCLC in lung cancer cell lines. Its action on the mRNA and protein expression levels of VEGFA, VEGFR2, NRP1, Casp9, Casp3, Bax, Bcl-2, PIK3CA, AKT, MTOR, PTEN and FOX3A was assessed. Furthermore, in this study the effects on cell migration, cell viability and proliferation was evaluated through wound healing, MTT and Crystal violet assays.

RESULTS:

This study demonstrated that Ornidazole effectively reduces cell viability and migration ability, inhibits angiogenesis and metastatic abilities in NSCLC cells.

CONCLUSIONS:

In conclusion, these results may shed light on the treatment of NSCLC, and we suggest the anti-parasitic drug Ornidazole as a new agent with potential anti-angiogenic and anti-mitotic activity by interfering with the molecular pathways that trigger tumor angiogenesis and migration.

01 Nov 2024·Analytical and Bioanalytical Chemistry

Development of purity certified reference materials to establish metrological traceability for the measurement of nitroimidazoles in agricultural products

Article

Author: Zhou, Jian ; Zhang, LiYuan ; Liu, QingYi ; Li, FuKai ; Yang, MengRui ; Wang, Min ; Jiang, Bin

It is of significant importance to public health that reliable monitoring of nitroimidazoles be conducted, while certified reference materials (CRMs) are essential for accurate and reliable detection. A project has been initiated with the objective of developing nitroimidazole purity CRMs to ensure that results from nationwide monitoring laboratories for nitroimidazoles in antibiotic residues can be compared and traced. The candidates were successively characterized in terms of their structure by means of infrared (IR) spectroscopy and mass spectrometry (MS). The mass balance (MB) method and the quantitative nuclear magnetic resonance (qNMR) method were utilized to determine the purity of nitroimidazoles with remarkable accuracy. Furthermore, a methodical investigation was conducted on homogeneity, stability, and uncertainty. Six nitroimidazole purity CRMs, including tinidazole (GBW09252), secnidazole (GBW09286), ronidazole (GBW09288), metronidazole (GBW(E)090755), dimetridazole (GBW(E)090819), and ornidazole (GBW(E)090820), were finally manufactured following authorization from China's State Administration for Market Regulation (SAMR). By using these CRMs, it is possible to improve the traceability, accuracy, and comparability of nitroimidazole measurements in a range of agricultural products, protecting public health.

100 Deals associated with Ornidazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05274	Ornidazole	P01AB03 J01XD03 G01AF06	DB13026

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Amebiasis	CN	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001
Anaerobic bacterial infection	CN	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001
Giardiasis	CN	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001
Trichomonas Infections	CN	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dysentery, Amebic	Phase 1	CN	-	10 Oct 2013
Liver Abscess, Amebic	Phase 1	CN	-	10 Oct 2013
Urogenital infection by Trichomonas vaginalis	Phase 1	CN	-	10 Oct 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AASLD2023	Not Applicable	Chemical and Drug Induced Liver Injury	82	Ornidazole alone	anfmdfgfxb(uucyjeypdm) = igsenvgigq dpbzmglxum (damxzchibz ) View more	-	10 Nov 2023